Media Release: January 31, 2012
ALLIANCE FOR A STRONGER FDA ANNOUNCES NEW LEADERSHIP FOR 2012
New Alliance Leadership Brings Legislative, Regulatory, Advocacy Expertise and Renewed Dedication to Increasing FDA Appropriations Despite a Tough Environment
WASHINGTON, D.C., January 31, 2012 — FasterCures executive director Margaret Anderson has been named president of the Alliance for a Stronger FDA for 2012. Anderson has been on the board of the Alliance since its inception and was the Alliance’s Vice-President in 2011. Every year since the Alliance began its advocacy on behalf of the FDA, the agency has received funding increases. FDA was one of the few federal programs to receive more dollars in both FY 2011 and FY 2012.
Other members of the Alliance’s leadership include Diane Dorman, National Organization for Rare Disorders (Vice President), Rich Buckley, AstraZeneca (Secretary), Caroline Smith DeWaal, Center for Science in the Public Interest (Treasurer) and executive committee members, Andrew Emmett, Biotechnology Industry Organization, Nancy Bradish Myers, Catalyst Healthcare Consulting Inc., and Kasey Thompson, American Society of Health-System Pharmacists.
With responsibility for products that comprise more than 20 percent of U.S. consumer spending, the FDA oversees industries that are key to the nation’s growth. A science-based and predictable FDA helps many industries, including food, drug, medical device, and cosmetics, to innovate and create high-paying American jobs, while improving our balance of trade. Multiple times every day, Americans use products for which FDA is responsible. There is no backstop, no other agency that performs this critical work.
“Focused advocacy for a strong and robust FDA is critical to ensuring the agency will be able to deliver on its mission of getting safe food and safe and effective medical therapies into the hands of consumers and patients, and ensuring the safety of those products,” said Anderson.
“At FasterCures, our mission is to speed up the process of turning medical discoveries into effective and accessible therapies. We need an FDA that’s fully resourced if we are to accelerate the therapeutic development process and deliver safe and effective drugs and devices that patients need,” added Anderson.
In the coming year, the Alliance, under Anderson’s leadership, will continue to build the case for increased appropriations for the FDA to allow the agency to meet its increased responsibilities, have the expertise and tools needed to take promising medical discoveries into the marketplace, and meet the demands of a global marketplace in food and medical products.
The Alliance, made up of nearly 200 members including consumer, patient, and industry organizations, is focused on ensuring the U.S. Food and Drug Administration has sufficient resources to continue to protect patients and consumers. The Alliance is the only multi-stakeholder group that advocates for increasing appropriated resources at FDA to match the agency’s responsibilities.
# # #